Stress Echocardiography Study With Regadenoson

Gilead Sciences

Status and phase: Terminated; Phase 2

Conditions: Coronary Artery Disease; Heart Disease

Treatments: Drug: regadenoson

Study type: Interventional

Funder types: Industry

Identifiers

NCT00907764

CVT 5127

Details and patient eligibility

About

Regadenoson is approved in the US under the brand name Lexiscan for myocardial perfusion imaging. This study will test whether regadenoson is an appropriate stress agent for stress echocardiography.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a clinically indicated dobutamine echocardiogram showing normal wall motion at rest and abnormal wall motion with stress
• Patients with a clinically indicated dipyridamole echocardiogram showing normal perfusion and wall motion at rest and abnormal perfusion with or without abnormal wall motion with stress

Exclusion criteria

• Any condition precluding the safe administration of dobutamine, dipyridamole or SonoVue for echocardiography
• Pregnant or breast-feeding, or (if pre-menopausal), not practicing acceptable method of birth control

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

22 participants in 4 patient groups

Regadenoson alone

Experimental group

Treatment:

Drug: regadenoson

Regadenoson with exercise

Experimental group

Treatment:

Drug: regadenoson

Regadenoson with contrast agent

Experimental group

Treatment:

Drug: regadenoson

Regadenoson with contrast agent (perfusion)

Experimental group

Treatment:

Drug: regadenoson